{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:52:32Z","timestamp":1791402752438,"version":"4.3.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03820-z","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:04:55Z","timestamp":1791356695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Confounder Identification in Diffuse Large B-Cell Lymphoma: Findings from an Expert Panel of German and Austrian Hematologists"],"prefix":"10.1007","author":[{"given":"Jan-Michel","family":"Heger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"G\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Habringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Kutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Rungaldier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Oddsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zacharioudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-2793","authenticated-orcid":false,"given":"J\u00f6rg","family":"Mahlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"3","key":"3820_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","volume":"34","author":"TJ Van der Weele","year":"2019","unstructured":"Van der Weele TJ. Principles of confounder selection. Eur J Epidemiol. 2019;34(3):211\u20139.","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"3820_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"issue":"30","key":"3820_CR3","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1002\/sim.8759","volume":"39","author":"DM Phillippo","year":"2020","unstructured":"Phillippo DM, Dias S, Ades AE, Welton NJ. Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study. Stat Med. 2020;39(30):4885\u2013911.","journal-title":"Stat Med"},{"key":"3820_CR4","doi-asserted-by":"publisher","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen [IQWIG]. Systematische Confounderidentifikation in der Indikation schubf\u00f6rmig remittierende multiple Sklerose (RRMS); IQWiG-Berichte \u2013 Nr. 1994. 2025 [accessed March 25, 2026]. URL: https:\/\/doi.org\/10.60584\/GA23-02.","DOI":"10.60584\/GA23-02"},{"key":"3820_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jclinepi.2022.03.018","volume":"148","author":"M Pufulete","year":"2022","unstructured":"Pufulete M, Mahadevan K, Johnson TW, Pithara C, Redwood S, Benedetto U, et al. Confounders and co-interventions identified in non-randomized studies of interventions. J Clin Epidemiol. 2022;148:115\u201323.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"3820_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00432-025-06249-z","volume":"151","author":"JK Schleifenbaum","year":"2025","unstructured":"Schleifenbaum JK, Heger JM, Jost J, et al. Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma. J Cancer Res Clin Oncol. 2025;151(7):203.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"17","key":"3820_CR7","first-page":"289","volume":"120","author":"M Ernst","year":"2023","unstructured":"Ernst M, D\u00fchrsen U, Hellwig D, et al. Diffuse Large B-Cell Lymphoma and Related Entities. Dtsch Arztebl Int. 2023;120(17):289\u201396.","journal-title":"Dtsch Arztebl Int"},{"issue":"5","key":"3820_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","volume":"60","author":"SS Wang","year":"2023","unstructured":"Wang SS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol. 2023;60(5):255\u201366.","journal-title":"Semin Hematol"},{"issue":"1","key":"3820_CR9","doi-asserted-by":"publisher","first-page":"2413801","DOI":"10.1080\/20565623.2024.2413801","volume":"10","author":"A Muramatsu","year":"2024","unstructured":"Muramatsu A, Kawakami T. Incidence of hematologic cancer types in Japan by ICD-O-3 code: Analysis of National Cancer Registry. Future Sci OA. 2024;10(1):2413801.","journal-title":"Future Sci OA"},{"key":"3820_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40487-022-00211-6","volume":"11","author":"P Borchmann","year":"2023","unstructured":"Borchmann P, Heger JM, Mahlich J, et al. Healthcare resource utilization and associated costs of German patients with diffuse large B-cell lymphoma: a retrospective health claims data analysis. Oncol Ther. 2023;11:65\u201381.","journal-title":"Oncol Ther"},{"key":"3820_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kansas","year":"2022","unstructured":"Kansas G, Ge W, Quek RGW, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025. Leuk Lymphoma. 2022;63:54\u201363.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"3820_CR12","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","volume":"55","author":"S Fiorenza","year":"2020","unstructured":"Fiorenza S, Ritchie DS, Ramsey SD, et al. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant. 2020;55(9):1706\u201315.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"3820_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000524","volume":"5","author":"R Heine","year":"2021","unstructured":"Heine R, Thielen F, Koopmanschap M, et al. Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future. Hemasphere. 2021;5(2):e524.","journal-title":"Hemasphere"},{"key":"3820_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363.","journal-title":"N Engl J Med"},{"issue":"9","key":"3820_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70207","volume":"9","author":"C Thieblemont","year":"2025","unstructured":"Thieblemont C, Gomes Da Silva M, Lepp\u00e4 S, et al. Large B-cell lymphoma (LBCL): EHA clinical practice guidelines for diagnosis, treatment, and follow-up. Hemasphere. 2025;9(9):e70207.","journal-title":"Hemasphere"},{"key":"3820_CR16","unstructured":"DGHO Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.V., OeGHO, SGMO, SGH+SSH. Diffuses gro\u00dfzelliges B-Zell-Lymphom. In: ONKOPEDIA-Leitlinien. Stand Dezember 2025. Onkopedia Leitlinie DLBCL (accessed on July, 16.2026)."},{"key":"3820_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.565236","volume":"11","author":"M Gotti","year":"2020","unstructured":"Gotti M, Defrancesco I, D\u2019angelo M, et al. Cancer immunotherapy using chimeric antigen receptor expressing T-cells: present and future needs of clinical cancer centers. Front Immunol. 2020;11:565236.","journal-title":"Front Immunol"},{"key":"3820_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40261-026-01549-9","volume":"46","author":"Y Arai","year":"2026","unstructured":"Arai Y, Bolt T, Onishi H, et al. Willingness to pay for treatment attributes in diffuse large B-cell lymphoma: a discrete choice study in Japan. Clinical Drug Invest. 2026;46:619\u201330.","journal-title":"Clinical Drug Invest"},{"key":"3820_CR19","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000436","author":"A Mussetti","year":"2023","unstructured":"Mussetti A, Fabbri N, Sureda A. CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers. Hematology Am Soc Hematol Educ Program. 2023. https:\/\/doi.org\/10.1182\/hematology.2023000436.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"25","key":"3820_CR20","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1161\/CIRCULATIONAHA.125.073645","volume":"151","author":"A Bellavia","year":"2025","unstructured":"Bellavia A, Murphy SA. Confounders, effect modifiers, and mediators: dealing with \u201cthird variables\u201d in cardiovascular epidemiology. Circulation. 2025;151(25):1755\u20137.","journal-title":"Circulation"},{"issue":"1","key":"3820_CR21","first-page":"196","volume":"41","author":"TJ Van der Weele","year":"2013","unstructured":"Van der Weele TJ, Shpitser I. On the definition of a confounder. Ann Stat. 2013;41(1):196\u2013220.","journal-title":"Ann Stat"},{"issue":"7","key":"3820_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032829","volume":"102","author":"Z Shang","year":"2023","unstructured":"Shang Z. Use of Delphi in health sciences research: a narrative review. Medicine (Baltimore). 2023;102(7):e32829.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"3820_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67(4):401\u20139.","journal-title":"J Clin Epidemiol"},{"key":"3820_CR24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"MA Shipp","year":"1993","unstructured":"Shipp MA. International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project Apredictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"3820_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jtct.2020.10.022","volume":"27","author":"M Garcia-Recio","year":"2021","unstructured":"Garcia-Recio M, Wudhikarn K, Pennisi M, et al. The International Prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2021;27:233\u201340.","journal-title":"Transplant Cell Ther"},{"key":"3820_CR26","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge WA, Martus P, Schmitt M, et al. GLA\/DRST real-world outcome analysis of CAR T-Cell therapies for large B-Cell lymphoma in Germany. Blood. 2022;140:349\u201358.","journal-title":"Blood"},{"key":"3820_CR27","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145\u201354.","journal-title":"Nat Med"},{"issue":"24","key":"3820_CR28","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi R, Le Gouill S, Bachy E, et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022;140(24):2584\u201393.","journal-title":"Blood."},{"issue":"17","key":"3820_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174334","volume":"15","author":"AM Spanjaart","year":"2023","unstructured":"Spanjaart AM, Pennings ERA, Mutsaers P, et al. The Dutch CAR-T tumorboard experience: population-based real-world data on patients with relapsed or refractory large B-cell lymphoma referred for CD19-directed CAR T-cell therapy in the Netherlands. Cancers. 2023;15(17):4334.","journal-title":"Cancers"},{"key":"3820_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2022.280805","volume":"108","author":"M Kwon","year":"2023","unstructured":"Kwon M, Iacoboni G, Reguera JL, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023;108:110\u201321.","journal-title":"Haematologica"},{"key":"3820_CR31","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1182\/blood.2022015789","volume":"139","author":"J Westin","year":"2022","unstructured":"Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139:2737\u201346.","journal-title":"Blood"},{"key":"3820_CR32","doi-asserted-by":"publisher","first-page":"751.E1","DOI":"10.1016\/j.jtct.2022.08.001","volume":"28","author":"K Nath","year":"2022","unstructured":"Nath K, Tomas AA, Flynn J, et al. Vitamin D insufficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in large B-Cell lymphoma. Transplant Cell Ther. 2022;28:751.E1-751.E7.","journal-title":"Transplant Cell Ther"},{"key":"3820_CR33","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1038\/s41467-026-72816-8","volume":"17","author":"Y Liu","year":"2026","unstructured":"Liu Y, Yang J, Iqbal M, et al. A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapy. Nat Commun. 2026;17:6025.","journal-title":"Nat Commun"},{"issue":"9","key":"3820_CR34","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","volume":"97","author":"U J\u00e4ger","year":"2012","unstructured":"J\u00e4ger U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97(9):1431\u20138.","journal-title":"Haematologica"},{"issue":"3","key":"3820_CR35","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14860","volume":"179","author":"M Pfreundschuh","year":"2017","unstructured":"Pfreundschuh M, Murawski N, Zeynalova S, et al. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. Br J Haematol. 2017;179(3):410\u201320.","journal-title":"Br J Haematol"},{"key":"3820_CR36","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1182\/blood-2023-186510","volume":"142","author":"V B\u00fccklein","year":"2023","unstructured":"B\u00fccklein V, Rejeski K, Perez A. Impact of sex on clinical outcomes after CD19 CAR T-cell therapy for large B-cell lymphoma: response and survival are significantly superior in female compared to male patients. Blood. 2023;142:3787.","journal-title":"Blood"},{"issue":"6","key":"3820_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70831","volume":"14","author":"JY Tan","year":"2025","unstructured":"Tan JY, Yeo YH, Kin HWK, et al. Sex differences in outcomes of chimeric antigen receptor (CAR) T-cell therapy. Cancer Med. 2025;14(6):e70831.","journal-title":"Cancer Med"},{"issue":"suppl_1","key":"3820_CR38","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1182\/blood-2022-162582","volume":"140","author":"J Mu\u00f1oz","year":"2022","unstructured":"Mu\u00f1oz J, Hu ZH, Kanters S, et al. Real-world bridging therapy (BT) of patients with relapsed or refractory (r\/r) large B-Cell lymphoma (LBCL) treated with chimeric antigen receptor (CAR) T-cell therapy: a systematic literature review (SLR) and meta-analysis. Blood. 2022;140(suppl_1):4627\u20139.","journal-title":"Blood"},{"key":"3820_CR39","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","volume":"7","author":"C Roddie","year":"2023","unstructured":"Roddie C, Neill L, Osborne W, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023;7:2872\u201383.","journal-title":"Blood Adv"},{"issue":"2","key":"3820_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/ejh.14423","volume":"115","author":"B von Tresckow","year":"2025","unstructured":"von Tresckow B, Abrisqueta P, Zamanillo I, et al. Prognostic factors and effect modifiers in patients with relapse or refractory diffuse large B-cell lymphoma after two lines of therapy: a systematic literature and expert clinical review. Eur J Haematol. 2025;115(2):104\u201316.","journal-title":"Eur J Haematol"},{"issue":"3","key":"3820_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2018.05.027","volume":"74","author":"AJ Vickers","year":"2018","unstructured":"Vickers AJ, Steineck G. Prognosis, effect modification, and mediation. Eur Urol. 2018;74(3):243\u20135.","journal-title":"Eur Urol"},{"issue":"8","key":"3820_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17081335","volume":"17","author":"S Riou","year":"2025","unstructured":"Riou S, Rungaldier S, Mahlich J. Identification of adjustment variables in indirect comparisons: a rapid review of CAR-T therapies for diffuse large B-cell lymphoma. Cancers (Basel). 2025;17(8):1335.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"3820_CR43","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2026-0033","volume":"15","author":"M Neumann","year":"2026","unstructured":"Neumann M, Jost J, Riou S, et al. Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review. J Comp Eff Res. 2026;15(7):e260033.","journal-title":"J Comp Eff Res"},{"key":"3820_CR44","unstructured":"Member State Coordination Group on Health Technology Assessment, Joint Clinical Assessment Report of Tovorafenib, Version 1.0, European Union, Brussels, 2026, available: https:\/\/health.ec.europa.eu\/document\/download\/395c2ba0-849a-4f3b-9251-aa2495b3efd7_en?filename=hta_jca_mp_202406_tovorafenib_report_en.pdf"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03820-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03820-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03820-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:02:56Z","timestamp":1791399776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03820-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":44,"alternative-id":["3820"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03820-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"10 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bastian von Tresckow is an advisor or consultant for AbbVie, Allogene, Amgen, BMS\/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Miltenyi, Novartis, Noscendo, Pentixapharm, Pfizer, Pierre Fabre, Qualworld, Regeneron, Roche, Serb, Sobi and Takeda; has received honoraria from AbbVie, AstraZeneca, BMS\/Celgene, Gilead Kite, Incyte, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Novartis, Roche, Serb and Takeda; reports research funding from Esteve (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), and Takeda (Inst); and reports travel support from AbbVie, AstraZeneca, Gilead Kite, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Pierre Fabre, Roche, Takeda, and Novartis; is member of steering committees for Regeneron (Inst) and Takeda. Jan Michel Heger reports research funding from Incyte, MorphoSys, and Novartis; has received honoraria or is an advisor or consultant for Incyte, Roche, Novartis, Miltenyi Biotec, SOBI, and SERB Pharmaceuticals; received travel support from SOBI, and SERB Pharmaceuticals. Nadine Kutsch reports research support from AstraZeneca, Honoraria from AbbVie, AstraZeneca, BMS, BeOne, Kite\/Gilead, Lilly, Miltenyi Biomedicine; Advisory Board memberships from: AstraZeneca, BMS, Janssen; Travel support from AbbVie, AstraZeneca, BeOne, Janssen, Kite\/Gilead, Lilly. Stefan Habringer reports honoraria for advisory board participation and talks from Incyte, Jazz, Onkowissen TV, Miltenyi, SERB SAS and Pentixapharm, travel support from AbbVie and co-founded Moonlight AI GmbH. Ruiyu Zhang, Stefanie Rungaldier, and J\u00f6rg Mahlich are employees of Miltenyi Biomedicine. Julia Oddsdottir, and Maria Zacharioudaki are employees of IQVIA. Philipp G\u00f6del, Ulrich J\u00e4ger, Julia Oddsdottir, and Maria Zacharioudaki have nothing to declare.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants were fully informed about the study\u2019s objectives and the intent to publish the results. Consent was given voluntarily through signed contracts. Data protection adhered to GDPR regulations, with analyses conducted pseudonymously to ensure privacy. Ethical committee consultation was not required as the study only involved physician responses, with no patient information and no interference with personal integrity.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}